Synthesis, cytotoxic effects and tubulin polymerization inhibition of 1,4-disubstituted 1,2,3-triazole analogs of 2-methoxyestradiol

Steroids

Volumn 87, Issue , 2014, Pages 46-53

  Solum, Eirik Johansson ^a   Vik, Anders ^a   Hansen, Trond Vidar ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

1,2,3 Triazoles; 2 Methoxyestradiol; Anti cancer; Cytotoxicity; Estrogens; Tubulin inhibition

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; 2 METHOXYESTRA 17 [1 (3,4,5 TRIMETHOXYBENZYL) 1H 1,2, 3 TRIAZOL 4 YL)DIOL; 2 METHOXYESTRA 17 [1 (3,4,5 TRIMETHOXYPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 (4 BROMOPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 (4 CHLOROPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 (4 FLOUROPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 (4 HYDROXYPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 (4 METHOXYPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 PHENYL 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 [4 (TERT BUTYL)PHENYL] 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 [4 (TRIFLUOROMETHOXYL)PHENYL] 1H 1,2, 3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRA 17 [1 [4 (TRIFLUOROMETHYL)PHENYL] 1H 1,2,3 TRIAZOL 4 YL)DIOL; 2 METHOXYESTRA 17 [1 [4 METHYLPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 2 METHOXYESTRADIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 (1 PHENYL 1H 1,2,3 TRIAZOL 4 YL)DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (3,4,5 TRIMETHOXYBENZYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (3,4,5 TRIMETHOXYPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (4 BROMOPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (4 CHLOROPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (4 FLOUROPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (4 HYDROXYPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (4 METHOXYBENZYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 (4 METHOXYPHENYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 [4 (TERT BUTYL)PHENYL] 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 [4 (TRIFLUOROMETHOXYL)PHENYL] 1H 1,2,3 TRIAZOL 4 YL]DIOL; 3 TERT BUTYLDIMETHYLSILOXY 2 METHOXYESTRA 17 [1 [4 (TRIFLUOROMETHYL)PHENYL] 1H 1,2,3 TRIAZOL 4 YL]DIOL; ANTINEOPLASTIC AGENT; METHOXYESTRA 17 [1 (4 METHOXYBENZYL) 1H 1,2,3 TRIAZOL 4 YL]DIOL; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2-METHOXYESTRADIOL; ESTRADIOL; TRIAZOLE DERIVATIVE; TUBULIN MODULATOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LIPOPHILICITY; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MTT ASSAY; MYELOID LEUKEMIA; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; K562 CELL LINE; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; ESTRADIOL; HUMANS; K562 CELLS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; TRIAZOLES; TUBULIN; TUBULIN MODULATORS;

EID: 84902649683     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.05.020     Document Type: Article

References (31)

1. A. Gupta, B.S. Kumar, and A.S. Negi Current status on development of steroids as anticancer agents J Steroid Biochem Mol Biol 137 2013 2242 2270
2. J.A.R. Salvador, J.F.S. Carvalho, M.A.C. Neves, S.M. Silvestre, A.J. Leitão, and M.C. Silva et al. Anticancer steroids: linking natural and semi-synthetic compounds Nat Prod Rep 30 2013 324 374
3. C.P. Martucci Metabolic fate of catechol estrogens G.R. Merriam, M.B. Lipsett, Catechol estrogens 1983 Raven Press New York 115 121
4. R.J. D'Amato, C.M. Lin, E. Flynn, J. Folkman, and E. Hamel 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site Proc Nat Acad Sci USA 91 1994 3964 3968 (Pubitemid 24139553)
5. T. Fotsis, Y. Zhang, M.S. Pepper, H. Adlercreutz, R. Montesano, and P.P. Nawroth et al. The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth Nature 268 1994 237 239 (Pubitemid 24108838)
6. S. Verenich, and P.M. Gerk Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges Mol Pharm 7 2010 2030 2039
7. J.F. Peyrat, J.D. Brion, and M. Alami Synthetic 2-methoxyestradiol derivatives: structure-activity relationships Curr Med Chem 19 2012 4142 4156
8. M. Sattler, L.R. Quinnan, Y.B. Pride, J.L. Gramlich, S.C. Chu, and G.C. Even et al. 2-Methoxyestradiol alters cell motility, migration, and adhesion Blood 102 2003 289 296 (Pubitemid 36759667)
9. S. Bu, A. Blaukat, X. Fu, N.E. Heldin, and M. Landstrom Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells FEBS Lett 531 2002 141 151 (Pubitemid 35341185)
10. E. Wassberg Angiostatic treatment of neuroblastoma Ups J Med Chem Sci 104 1999 1 24
11. S.L. Mooberry Mechanism of action of 2-methoxyestradiol: new developments Drug Resist Updates 6 2003 355 361 (Pubitemid 38173586)
12. C. Sweeney, G. Liu, C. Yiannoutsos, J. Kolesar, D. Horvath, and M.J. Staab et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer Clin Cancer Res 11 2005 6625 6633 (Pubitemid 41339003)
13. W.L. Dahut, N.J. Lakhani, J.L. Gulley, P.M. Arlen, E.C. Kohn, and H. Kotz et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors Cancer Biol Ther 5 2006 22 27 (Pubitemid 43234973)
14. J. James, D.J. Murry, A.M. Treston, A.M. Storniolo, G.W. Sledge, and C. Sidor et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer Invest New Drugs 25 2006 41 48
15. S.V. Rajkumar, P.G. Richardson, M.Q. Lacy, A. Dispenzieri, P.R. Greipp, and T.E. Witzig et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma Clin Cancer Res 13 2007 6162 6167 (Pubitemid 350075076)
16. T.L. Tinley, R.M. Leal, A.D. Randall-Hlubeck, J.W. Cessac, L.R. Wilkens, and P.N. Rao et al. Novel 2-methoxyestradiol analogues with antitumor activity Cancer Res 63 2003 1538 1539
17. N.J. Lakhani, A. Sparreboom, X. Xu, T.D. Veenstra, J. Venitz, and W.L. Dahut et al. Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol J Pharm Sci 96 2007 1821 1831 (Pubitemid 47122958)
18. L. Evensen, K. Odlo, D.R. Micklem, A. Littlewood-Evans, J. Wood, and C. Kuzniewski et al. Contextual compound screening for improved therapeutic discovery Chem Bio Chem 14 2013 2512 2518
19. O.W. Akselsen, K. Odlo, J.J. Cheng, G. Maccari, M. Botta, and T.V. Hansen Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1 Bioorg Med Chem 20 2012 234 242
20. K. Odlo, J. Fournier dit Chabert, S. Ducki, O.A.B.S.M. Gani, I. Sylte, and T.V. Hansen 1,2,3-triazole analogs of combretastatin A-4 as potential microtubule-binding agents Bioorg Med Chem 18 2010 6874 6885
21. K. Odlo, J. Hentzen, J. Fournier dit Chabert, S. Ducki, O.A.B.S.M. Gani, and I. Sylte et al. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin Bioorg Med Chem 16 2008 4829 4838 (Pubitemid 351625899)
22. V.V. Rostovtsev, L.G. Green, V.V. Fokin, and K.B. Sharpless A stepwise Hüisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew Chem Int Ed 41 2002 2596 2599 (Pubitemid 34803480)
23. C.W. Tornøe, C. Christensen, and M. Meldal Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides J Org Chem 67 2002 3057 3064 (Pubitemid 34457265)
24. G.C. Tron, T. Pirali, R.A. Billington, P.L. Canonico, G. Sorba, and A.A. Genazzani Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes Med Res Rev 28 2008 278 308 (Pubitemid 351281190)
25. J.E. Moses, and A.D. Moorhouse The growing applications of click chemistry Chem Soc Rev 36 2007 1249 1262
26. J.M. Edmondson, L.S. Armstrong, and A.O. Martinez A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures J Tissue Cult Meth 11 1988 15 17
27. N.J. Lawrence, A.T. McGown, S. Ducki, and J.A. Hadfield The interaction of chalcones with tubulin Anti-Cancer Drug Des 15 2000 135 141 (Pubitemid 30410472)
28. R.H. Peters, D.F. Crowe, M.A. Avery, W.K.M. Chong, and M. Tanabe Analogues of [(triethylsilyl)ethynyl]estradiol as potential antifertility agents J Med Chem 31 1988 572 576 (Pubitemid 18070574)
29. E.J. Corey, and B.B. Snider Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives J Am Chem Soc 94 1972 6190 6192
30. M.A. Jordan, and L. Wilson The role of microtubules in cell biology T. Fojo, Neurobiology, and oncology 2008 Humana Press Totowa 47 81
31. S.X. Cai Small molecule vascular disrupting agents: potential new drugs for cancer treatment Recent Patents Anticancer Drug Discov 2 2007 79 101 (Pubitemid 46723154)